AIM2 siRNA Adjuvant for Melanoma Therapy

Background

60%-70% of metastatic melanoma patients fail immunotherapy due to limited local inflammation

• Systemic AIM2 siRNA therapy unmasks metastatic melanoma tumors to immune system surveillance
• Systemic AIM2 siRNA therapy enhances the anti-PD-1 immunotherapy response.

Technology Overview

• Sensitizing melanoma to anti-PD-1 immunotherapy by converting “cold” tumors into “hot” using siRNA therapeutics.
• Systemic siRNA Therapy Sensitizes Melanoma to Anti-PD-1 Immunotherapy
• First-in-class siRNA Immunotherapy Adjuvant Predicted to Improve Progression Free Survival in Metastatic Melanoma Patients
  • AIM2 siRNA therapy sensitized melanoma to anti-PD-1 immunotherapy by converting “cold” tumors into “hot” tumors
  • Dendrimer conjugate (non-proprietary) allows for systemic delivery of siRNA

Further Detail

Publication: Fukuda K, Okamura K, Riding RL, Fan X, Afshari K, Haddadi NS, McCauley SM, Guney MH, Luban J, Funakoshi T, Yaguchi T, Kawakami Y, Khvorova A, Fitzgerald KA, Harris JE. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med. 2021 Sep 6;218(9):e20200962. doi: 10.1084/jem.20200962. Epub 2021 Jul 29. PMID: 34325468; PMCID